Innovations

 

DC Bead Lumi

BTG plc
+44 (0) 203-318-7881
customer.services@btgplc.com
www.btg-im.com
www.dcbeadlumi.com

KEY FEATURES

  • Radiopaque drug-eluting bead
  • Visible under imaging during and after embolization
  • ELasting confirmation of bead location
  • Drug-loadable with doxorubicin or irinotecan
  • New level of control for transarterial chemoembolization (TACE) procedures

DC Bead Lumi are intended to be used for the embolization of hypervascular tumors and arteriovenous malformations. They are precisely calibrated, radiopaque embolic drug-eluting beads developed using the same core chemistry as the clinically proven DC Bead. DC Bead Lumi contains a covalently bound radiopaque moiety to offer inherent, lasting radiopacity. The beads are visible in various imaging modes (CT, cone-beam CT, and fluoroscopy) during the procedure and at follow-up.

“The ability to see bead location during TACE procedures is a key step in enhancing the quality and potentially minimizing complications of the procedure, and can help improve treatment outcomes compared with current techniques,” said Tobias Jakobs, MD, of the Hospital of the Order of St. John of God, Munich, Germany. “More importantly, the lasting radiopacity of DC Bead Lumi means I can show patients that treatment has been placed exactly where it’s needed.”

The DC Bead Lumi has received Class III CE Mark certification in Europe, and is also approved in Canada.

 

Contact Info

For advertising rates and opportunities, contact:
Craig McChesney
484-581-1816
cmcchesney@bmctoday.com

Stephen Hoerst
484-581-1817
shoerst@bmctoday.com

Charles Philip
484-581-1873
cphillip@bmctoday.com

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.